ReviewAntibiotics (Basel, Switzerland)2024
Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.
Review in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Therapeutic Potential and Functional Mechanisms of Probiotics as Prospective anti-inflammatory Agents.Probiotics and antimicrobial proteins · 2026Review
- Gut microbiota impact on lung diseases: a mini review of clinical evidence.Infection and immunity · 2026Review
- Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, neurological and autoimmune disorders.Antonie van Leeuwenhoek · 2026Review
- Probiotic Modulation of the Gut-Ovary and Gut-Myometrium Axes: An In Vitro Study.Microorganisms · 2026Article
- Postbiotics and Parabiotics: A Viable Health Promoting Alternative for Poultry Industry-A Comprehensive Review.Probiotics and antimicrobial proteins · 2026Review
- Gut microbiota as modulators of obesity and overweight: a registry-based systematic review of clinical trial evidence.Frontiers in nutrition · 2026Article
- Bloodstream Infection-induced Neuroinflammation: from Systemic Infection To Brain Invasion.Current microbiology · 2025Review
- Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.Drug discovery today · 2025Review
- The Promising Biological Role of Postbiotics in Treating Human Infertility.Probiotics and antimicrobial proteins · 2025Review
- Incidence of Gallstones in Patients with Obesity After Bariatric Surgery in Northern Saudi Arabia: A Cross-Sectional Study.Clinics and practice · 2025Article
- Nature's Arsenal: Uncovering Antibacterial Agents Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Evaluating the Efficacy of Secondary Metabolites in Antibiotic-Induced Dysbiosis: A Narrative Review of Preclinical Studies.Antibiotics (Basel, Switzerland) · 2025Review
- Gut microbiota profile and atopic dermatitis in the first year of life.Journal of medicine and life · 2024Article
- Editorial: Interactions between bioactive food ingredients and intestinal microbiota, volume II.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota establishes a mutually beneficial relationship with the host starting from birth, impacting diverse metabolic and immunological processes. Dysbiosis, characterized by an imbalance of microorganisms, is linked to numerous medical conditions, including gastrointestinal disorders, cardiovascular diseases, and autoimmune disorders. This imbalance promotes the proliferation of toxin-producing bacteria, disrupts the host's equilibrium, and initiates inflammation. Genetic factors, dietary choices, and drug use can modify the gut microbiota. However, there is optimism. Several therapeutic approaches, such as probiotics, prebiotics, synbiotics, postbiotics, microbe-derived products, and microbial substrates, aim to alter the microbiome. This review thoroughly explores the therapeutic potential of these microbiota modulators, analysing recent studies to evaluate their efficacy and limitations. It underscores the promise of microbiota-based therapies for treating dysbiosis-related conditions. This article aims to ensure practitioners feel well-informed and up to date on the most influential methods in this evolving field by providing a comprehensive review of current research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.